Overview

  • Product nameAnti-Bcr antibody [EP535Y]
    See all Bcr primary antibodies
  • Description
    Rabbit monoclonal [EP535Y] to Bcr
  • Tested applicationsSuitable for: ICC/IF, WB, IHC-P, Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to residues in the C-terminus of human Bcr.

  • Positive control
    • K562 cell lysate, human lymphoma, HeLa cells.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Properties

Applications

Our Abpromise guarantee covers the use of ab40779 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/250.
WB 1/2000 - 1/10000. Detects a band of approximately 150 kDa (predicted molecular weight: 143 kDa).
IHC-P Use at an assay dependent concentration.
Flow Cyt 1/20.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

IP 1/60.

Target

  • FunctionGTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.
  • Involvement in diseaseNote=A chromosomal aberration involving BCR is a cause of chronic myeloid leukemia. Translocation t(9;22)(q34;q11) with ABL1. The translocation produces a BCR-ABL found also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • Sequence similaritiesContains 1 C2 domain.
    Contains 1 DH (DBL-homology) domain.
    Contains 1 PH domain.
    Contains 1 Rho-GAP domain.
  • DomainThe region involved in binding to ABL1 SH2-domain is rich in serine residues and needs to be Ser/Thr phosphorylated prior to SH2 binding. This region is essential for the activation of the ABL1 tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene.
    The DH domain is involved in interaction with CCPG1.
  • Post-translational
    modifications
    Autophosphorylated. Phosphorylated by FES/FPS on tyrosine residues, leading to down-regulation of the BCR kinase activity. Phosphorylation at Tyr-177 by HCK is important for interaction with GRB2.
  • Information by UniProt
  • Database links
  • Alternative names
    • ALL antibody
    • bcr antibody
    • BCR/ABL FUSION GENE, INCLUDED antibody
    • BCR/FGFR1 chimera protein antibody
    • BCR/FGFR1 FUSION GENE, INCLUDED antibody
    • BCR/PDGFRA FUSION GENE, INCLUDED antibody
    • BCR_HUMAN antibody
    • BCR1 antibody
    • Breakpoint cluster region antibody
    • Breakpoint cluster region protein antibody
    • CML antibody
    • D22S11 antibody
    • D22S662 antibody
    • FGFR1/BCR chimera protein antibody
    • PHL antibody
    • Renal carcinoma antigen NY-REN-26 antibody
    see all

Anti-Bcr antibody [EP535Y] images

  • ab40779, staining human lymphoma by immunohistochemistry, paraffin embedded tissue.
  • ab40779, staining HeLa cells by immunofluorescence.

References for Anti-Bcr antibody [EP535Y] (ab40779)

This product has been referenced in:
  • Guo Z  et al. Proteomics strategy to identify substrates of LNX, a PDZ domain-containing E3 ubiquitin ligase. J Proteome Res 11:4847-62 (2012). Read more (PubMed: 22889411) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab40779.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"